BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 16, Issue 10
This Article
Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (5989)
All Articles published online
The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.
Item 
Count 
PDF449
HTML5096
Figures (1-1)301
Tables (1-2)143
 Sum=5989
Mar 14, 2010 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef
For: Saridaki Z, Georgoulias V, Souglakos J. Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol 2010; 16(10): 1177-1187 [PMID: 20222160 DOI: 10.3748/wjg.v16.i10.1177]
URL: https://www.wjgnet.com/1007-9327/full/v16/i10/1177.htm
Number Citing Articles
1
Katharina Balschun, Jochen Haag, Ann-Kathrin Wenke, Witigo von Schönfels, Nicolas T. Schwarz, Christoph Röcken. KRAS, NRAS, PIK3CA Exon 20, and BRAF Genotypes in Synchronous and Metachronous Primary Colorectal Cancers. The Journal of Molecular Diagnostics 2011; 13(4): 436 doi: 10.1016/j.jmoldx.2011.03.002
2
Z Saridaki, X Saegart, V De Vriendt, D Hatzidaki, S Palmans, L De Smedt, G De Hertogh, S Tejpar. KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?. British Journal of Cancer 2015; 113(6): 914 doi: 10.1038/bjc.2015.307
3
Zi-Xu Yuan, Xiao-Yan Wang, Qi-Yuan Qin, De-Feng Chen, Qing-Hua Zhong, Lei Wang, Jian-Ping Wang, Todd W. Miller. The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis. PLoS ONE 2013; 8(6): e65995 doi: 10.1371/journal.pone.0065995
4
Joseph Ryan Polli, Ping Chen, Brandon M. Bordeau, Joseph P. Balthasar. Targeted Delivery of Endosomal Escape Peptides to Enhance Immunotoxin Potency and Anti-cancer Efficacy. The AAPS Journal 2022; 24(3) doi: 10.1208/s12248-022-00698-x
5
Christine L. H. Snozek. Pharmacogenomics in Clinical Therapeutics. 2012; : 39 doi: 10.1002/9781119959601.ch4
6
Zenia Saridaki, Natalia Asimakopoulou, Ioannis Boukovinas, John Souglakos. How to Identify the Right Patients for the Right Treatment in Metastatic Colorectal Cancer (mCRC). Current Colorectal Cancer Reports 2015; 11(4): 151 doi: 10.1007/s11888-015-0270-9
7
Seyed Mohammad Hosseini, Javad Mohammadnejad, Hassan Yousefnia, Behrouz Alirezapour, Ali Hossein Rezayan. Development of 177Lu-Cetuximab-PAMAM dendrimeric nanosystem: a novel theranostic radioimmunoconjugate. Journal of Cancer Research and Clinical Oncology 2023; 149(10): 7779 doi: 10.1007/s00432-023-04724-z
8
Balázs Szabó, Györgyi A. Nelhűbel, Adél Kárpáti, István Kenessey, Balázs Jóri, Csilla Székely, István Peták, Gábor Lotz, Zita Hegedűs, Balázs Hegedűs, Tibor Füle, Balázs Döme, József Tímár, József Tóvári. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncology 2011; 47(6): 487 doi: 10.1016/j.oraloncology.2011.03.020
9
Petra Schroeder, Carsten Lindemann, Kirsten Dettmar, Jürgen Brieger, Jan Gosepath, Benjamin Pogorzelski, Diane Seimetz, Judith Atz. Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment. Clinical and Translational Oncology 2011; 13(12): 889 doi: 10.1007/s12094-011-0751-5
10
Andrew Hendifar, Carlyn-Rose Tan, Anand Annamalai, Richard Tuli. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer. Expert Review of Anticancer Therapy 2014; 14(9): 1051 doi: 10.1586/14737140.2014.922881
11
Zacharenia Saridaki, Maria Tzardi, Chara Papadaki, Maria Sfakianaki, Fraga Pega, Aristea Kalikaki, Eleftheria Tsakalaki, Maria Trypaki, Ippokratis Messaritakis, Efstathios Stathopoulos, Dimitris Mavroudis, Vassilis Georgoulias, John Souglakos, Meenhard Herlyn. Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients. PLoS ONE 2011; 6(1): e15980 doi: 10.1371/journal.pone.0015980
12
Jason A. Wilken, Andre T. Baron, Nita J. Maihle. The epidermal growth factor receptor conundrum. Cancer 2011; 117(11): 2358 doi: 10.1002/cncr.25805
13
Anja Pickhard, Simone Gröber, Anna Katharina Haug, Guido Piontek, Markus Wirth, Ulrich Straßen, Martina Rudelius, Rudolf Reiter. Survivin and pAkt as potential prognostic markers in squamous cell carcinoma of the head and neck. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2014; 117(6): 733 doi: 10.1016/j.oooo.2014.02.005
14
Annett Mueller, Erika Bachmann, Monika Linnig, Katrin Khillimberger, Carl Christoph Schimanski, Peter R. Galle, Markus Moehler. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemotherapy and Pharmacology 2012; 69(6): 1601 doi: 10.1007/s00280-012-1869-z
15
Xuejun Fan, Randall J Brezski, Ming Fa, Hui Deng, Allison Oberholtzer, Anneliese Gonzalez, William P Dubinsky, William R Strohl, Robert E Jordan, Ningyan Zhang, Zhiqiang An. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy. Breast Cancer Research 2012; 14(4) doi: 10.1186/bcr3240
16
Maria McIntire, Mark Redston. Targeted Therapies and Predictive Markers in Epithelial Malignancies of the Gastrointestinal Tract. Archives of Pathology & Laboratory Medicine 2012; 136(5): 496 doi: 10.5858/arpa.2011-0167-RA
17
Tarik Ghadban, Judith L. Dibbern, Matthias Reeh, Jameel T. Miro, Tung Y. Tsui, Ulrich Wellner, Jakob R. Izbicki, Cenap Güngör, Yogesh K. Vashist. HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer. Apoptosis 2017; 22(3): 369 doi: 10.1007/s10495-016-1332-4
18
Slah Ouerhani, Karim Bougatef, Ismail Soltani, Amel Ben Ammar Elgaaied, Salem Abbes, Samia Menif. The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer. Molecular Biology Reports 2013; 40(6): 4109 doi: 10.1007/s11033-013-2512-8
19
Yan-Jun Qu, Qian-Shi Zhang, Bo Wang, Feng Zhang, Evenki Pan, Chun-Yan Zhao, Si-Ye Liu, Li-Ping Fang. Comprehensive next-generation sequencing reveals double primary colorectal carcinoma missed by diagnostic imaging: A case report. World Journal of Gastrointestinal Oncology 2023; 15(10): 1823-1828 doi: 10.4251/wjgo.v15.i10.1823
Write to the Help Desk
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345